We offer customized production of tumor microtissue models using a variety of common oncology cell lines in monoculture or in co-culture with mouse or human stromal cells.
We can also optimize production of microtissues using cell lines you supply or modified cell lines. Production schedule and order by dates vary depending on the model type, so please contact us to coordinate your order with our customer service team.
Our oncology experts have identified optimal culture conditions for large-scale, reproducible production of 3D spheroid models that better reflect complex tumor biology by combining relevant tumor, stromal, and immune components. We give you the flexibility to select assay-ready microtissues produced from commonly used cancer cell lines or work with our oncology team to develop custom models designed specifically for your experimental objectives.
InSphero assay-ready 3D InSight™ Tumor Microtissues are designed to simplify and accelerate oncology drug efficacy testing. Using the 3D Select™ Process, our oncology experts have identified optimal culture conditions for large-scale, reproducible production of 3D spheroid models that better reflect complex tumor biology.
- Leverage physiologically relevant 3D tumor co-cultures composed of tumor and stromal components — with no artificial matrices
- Assess single agent or combinatorial efficacy of small molecule, biological, ADC, or immunomodulatory drugs using 3D optimized endpoints
- Quality controlled pre-validated models that optimize your staff resources and ensure robuts, reproducible results
We can work with you to develop a custom model to fit your project using our 3D Select™ Process and patented InSphero scaffold-free assay platforms. Select or provide a tumor cell line or PDX sample, and we’ll optimize conditions for microtissue formation to develop monoculture or co-culture (with fibroblasts) models to fit your needs. Once established, the model can be used in 3D InSight™ Oncology Services or delivered assay-ready for use in your lab.
“Our oncology team is dedicated to developing 3D tumor models that enable cancer researchers to focus on finding cures—without worrying about spheroid production issues. Through our 3D Select™ Process, we’ve identified optimal culture conditions for large-scale, reproducible production of 3D tumor models that can be used to assess efficacy of small molecule, biological, ADC, or immunomodulatory drugs using 3D-optimized endpoints.”
IRINA AGARKOVA, PHD
Senior Researcher, Oncology Solutions